Eliana Cristina Martins Miranda

Universidade do Tocantins

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Cármino Antônio De Souza

Universidade Estadual de Campinas (UNICAMP)

106

Afonso Celso Vigorito

Universidade Estadual de Campinas (UNICAMP)

Katia B Pagnano

Universidade Estadual de Campinas (UNICAMP)

Francisco Aranha

Universidade Estadual de Campinas (UNICAMP)

Irene Lorand‐Metze

Universidade Estadual de Campinas (UNICAMP)

Márcia Torresan Delamain

Faculdade de Ciências Médicas de Minas Gerais

Gislaine Borba Oliveira

Universidade Estadual de Campinas (UNICAMP)

Carlos Chiattone

Hospital Samaritano de São Paulo

Carlos Chiattone

Hospital Samaritano de São Paulo

Juliana Pereira

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Cooperative Institutions

Universidade Estadual de Campinas (UNICAMP)

247

Universidade de São Paulo

107

Hospital de Clínicas da Unicamp

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Massachusetts General Hospital

The University of Texas MD Anderson Cancer Center

Universidade Federal de São Paulo

Universidade Federal do Rio de Janeiro

Instituto Nacional do Câncer

Hospital São Paulo

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Risk assessment for multiple myeloma: preliminary results of the brazilian myeloma study group Avaliação de risco em mioloma múltiplo: resultados preliminares do grupo brasileiro de estudos de mieloma

DOAJ (DOAJ: Directory of Open Access Journals) (2008)

Ângelo Maiolino Vânia Hungria Gislaine D. Oliveira Eliana Cristina Martins Miranda Roberto Magalhães

Source

Cite

Citations (0)

Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol

Advances in Hematology (2010)

Katia B Pagnano Gustavo de Carvalho Duarte Irene Lorand‐Metze Márcia Torresan Delamain Eliana Cristina Martins Miranda

We analyzed the outcome of a series of 19 newly diagnosed patients with acute promyelocytic leukemia treated with AIDA modified protocol, using mitoxantrone in place of idarubicin. Eleven patients achieved morphologic CR (58%). The remaining 8 patients had induction failure due to death during induction. Ten of eleven patients in CR achieved molecular remission after induction therapy and all the 8 patients had molecular remission after consolidation. Eight patients completed the three consolidation courses as scheduled and then proceeded to maintenance therapy. After a median follow up of 52 months, no molecular or hematological relapse has occurred. The 4-year disease-free survival is 82%. The study showed the antileukemic efficacy of mitoxantrone and that it could be used as a reasonable option in anthracycline-based strategies in APL.

Mitoxantrone

Idarubicin

10.1155/2010/672137

Cite

Citations (2)

Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival

Transplantation and Cellular Therapy (2023)

Afonso Celso Vigorito Eliana Cristina Martins Miranda Vergílio Antônio Rensi Colturato Vaneuza Araújo Moreira Funke Giancarlo Fatobene

Failure-free survival (FFS), defined as the absence of new systemic treatment, recurrence of original malignancy and mortality not associated with recurrence after allogeneic hematopoietic stem cell transplantation (HCT), is a robust clinical measure to interpret results of initial systemic treatment of chronic graft-versus-host disease (cGVHD). We evaluate FFS after initial treatment of cGVHD in a mixed-race cohort from a resource-constrained country. This retrospective study included 354 consecutive patients after their first HCT between January 2014 and August 2020, who received initial systemic treatment for moderate or severe cGVHD at 13 Brazilian centers. Cox regression models were used to identify risk factors for treatment failure. The overall median follow-up among survivors was 28 months (range 1-71) after initial treatment. FFS was 89% at 6 months, 71% at 1 year and 52% at 2 years. New systemic treatment was the major cause of failure. In multivariable models, prior grades II-IV acute GVHD, a National Institutes of Health severity score of 3 in liver, gastrointestinal tract or lung involvement, and onset of initial treatment of cGVHD within 12 months after transplantation were all associated with an increased risk of treatment failure. Our results could serve as a benchmark for the design of future clinical trials evaluating initial treatment of cGVHD in resource-constrained locations.

10.1016/j.jtct.2023.01.007

Cite

Citations (0)

The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)

Blood (2024)

Thaís Fischer Eliana Cristina Martins Miranda Juliana Pereira Guilherme Duffles Jamila Vaz Tavarez

10.1182/blood-2024-211164

Cite

Citations (0)

99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma

Nuclear Medicine Communications (2020)

Camila Mosci Fernando Vieira Pericole Gislaine Borba Oliveira Márcia Torresan Delamain Maria Emília Seren Takahashi

F-fluorodeoxiglucose (F-FDG)-PET/CT has been widely used to evaluate multiple myeloma. Tc-sestamibi (MIBI) scintigraphy has also been proposed for assessing multiple myeloma, but its use with state-of-the-art single-photon emission computed tomography/computed tomography (SPECT/CT) technology has not been fully evaluated.This study aimed to compare these two imaging modalities in multiple myeloma staging.Sixty-two patients with recently diagnosed multiple myeloma were submitted to whole-body F-FDG-PET/CT and whole-body MIBI scans plus SPECT/CT of the chest and abdomen/pelvis. Number of focal lesions, contiguous soft tissue involvement (CSTI), extramedullary lesions (EMLs) and diffuse bone marrow (BM) involvement were recorded.PET/CT was positive in 59 patients (95%) and MIBI SPECT/CT in 58 (93%) (P = 0.69). MIBI detected more diffuse bone marrow involvement than PET/CT (respectively 78 vs. 58% of the patients), while PET/CT demonstrated more focal lesions than MIBI SPECT/CT (81 vs. 54% of the patients) (P = 0.002). PET/CT detected EMLs in four subjects and MIBI in one subject. CSTI was found in 28 (45%) and 23 (37%) patients on PET/CT and MIBI images, respectively (P = 0.36). Three patients with lytic lesions and no FDG uptake were MIBI positive, and two subjects with lytic lesions without MIBI uptake were FDG positive.MIBI SPECT/CT performs similarly to F-FDG-PET/CT in identifying sites of active disease in multiple myeloma staging. MIBI is more efficient than FDG for detecting the diffuse involvement of bone marrow but less efficient for detecting focal lesions. Some patients presented a 'mismatch' pattern of FDG/MIBI uptake.

PET-CT

10.1097/mnm.0000000000001259

Cite

Citations (9)

TÓPICOS ESPECIAIS EM EDUCAÇÃO: ANÁLISE E REFLEXÃO DAS QUESTÕES DO ENSINO - VOLUME 1

Editora Schreiben eBooks (2024)

Antônio Reis de Sá Bruna de Oliveira Assunção DOS SANTOS Cyrille Costa Carolina Votto Silva Elizabete Essamai Mangá

O e-book intitulado TÓPICOS ESPECIAIS EM EDUCAÇÃO: ANÁLISE E REFLEXÃO DAS QUESTÕES DO ENSINO – VOLUME 1 foi elaborado por um grupo de educadores comprometidos com a melhoria da educação. Em vez de desmantelar o que já existe, nosso objetivo é construir uma base sólida, a partir de pesquisas e perspectivas diversificadas de todos os participantes do processo educacional, para que a educação brasileira possa se beneficiar dessas práticas inovadoras. Organizado em diferentes seções, o e-book abrange diversas áreas que compõem o contexto educacional, englobando um amplo espectro de temas relevantes à atualidade. Cada tópico foi cuidadosamente escolhido por sua importância nos debates acadêmicos e na prática escolar, mesmo reconhecendo o distanciamento que, por vezes, se verifica entre esses dois ambientes.

10.29327/5443479

Cite

Citations (0)

Epidemiology, Clinical Features, and Outcomes of Peripheral T-Cell Lymphoma in Latin America

Luis Malpica Henry Idrobo Astrid Pavlovsky Eliana Cristina Martins Miranda Denisse Castro

Peripheral T-cell lymphoma

10.2139/ssrn.5004488

Cite

Citations (0)

Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome.

PubMed (2005)

Cármino Antônio De Souza Afonso Celso Vigorito Milton Artur Ruiz Márcio Nucci Frederico Luiz Dulley

The management of chronic myeloid leukemia (CML) has changed radically since the introduction of imatinib therapy. The decision of whether to offer a patient a hematopoietic stem cell transplant (HSCT) must be based on the probability of success of the procedure. The aim of this retrospective analysis of 1,084 CML patients who received an allogeneic HSCT in 10 Brazilian Centers between February 1983 and March 2003 was to validate the EBMT risk score.The study population comprised 647 (60%) males and 437 (40%) females, with a median age of 32 years old (range 1 - 59); 898 (83%) were in chronic phase, 146 (13%) were in accelerated phase and 40 (4%) were in blast crisis; 151 (14%) were younger than 20 years old, 620 (57%) were between 20 and 40 and 313 (29%) were older than 40; 1,025 (94%) received an HLA fully matched sibling transplant and only 59 (6%) received an unrelated transplant. In 283 cases (26%) a male recipient received a graft from a female donor. The interval from diagnosis to transplantation was less than 12 months in 223 (21%) cases and greater in 861 (79%). The overall survival, disease-free survival, transplant-related mortality and relapse incidence were 49%, 50%, 45% and 25%, respectively.Of the 1084 patients, 179 (17%) had a risk score of 0 or 1, 397 (37%) had a score of 2, 345 (32%) had a score of 3, 135 (12%) had a score of 4 and 28 (2%) a score of 5 or 6. The overall survival (OS) rate in patients with risk scores 0-1 and 2 was similar (58% and 55%, respectively) but significantly better than that in patients with scores 3 or more (score 3 - 44%, 4 - 36 % and 5-6 - 27%, respectively) pp<0.001). Disease-free survival (DFS) and transplant related mortality (TRM) in a patients with a score of 3 or more were 46% and 49%, respectively and the relapse rate beyond score 5-6 was 77%. Disease status had a negative impact on all outcomes (OS, DFS, TRM, and relapse). The OS rate for male recipients of a graft from a female donor was 40% compared to 52% among the other donor-recipient pairs (p=0.004). DFS and TRM were significant for disease phase and female donor-male recipient (p<0.001 and p<0.003, respectively). In our experience, age and interval between diagnosis and transplant did influence OS, DFS, TRM, and relapse rate.Our results validate the EBMT risk score in the context of a developing country and confirm its usefulness for making point decisions in the imatinib era.

Source

Cite

Citations (37)

Author response for "Oral shedding of CMV and HSV‐1 in hematopoietic stem cell transplantation patients"

André Luiz Ferreira Costa Bruna A. Santos Vinícius Rabelo Torregrossa Eliana Cristina Martins Miranda Afonso Celso Vigorito

Viral Shedding

10.1111/odi.13690/v2/response1

Cite

Citations (0)

Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients

Journal of Medical Economics (2010)

Keith Tolley Nick Oliver Eliana Cristina Martins Miranda Kristen Migliaccio–Walle Duygu Bozkaya

Objective:The study evaluated the cost effectiveness of deferasirox (Exjade) compared to non-proprietary desferrioxamine (DFO) for the control of transfusional iron overload in lower risk myelodysplastic syndromes (MDS) patients. A UK National Health Service perspective was adopted.Methods:Recent clinical evidence has demonstrated the efficacy and safety of deferasirox in transfusion-dependent MDS patients with elevated serum ferritin levels. An economic model was used to extrapolate the clinical benefits of iron chelation therapy (ICT) in a cohort of lower risk MDS patients. Costs for drug acquisition, drug administration and monitoring, and quality of life (utility) outcomes associated with mode of drug administration were derived from a variety of sources. The incremental cost per QALY gained for deferasirox was estimated. Costs and outcomes were discounted at 3.5% in line with UK standards.Results:The base-case cost effectiveness of deferasirox versus DFO was estimated to be £20,822 per QALY gained, the key driver being the additional quality of life benefits associated with a simpler mode of administration for deferasirox. A mean survival benefit for both forms of ICT of 4.5 years was estimated. The results were sensitive to drug dose, days of DFO administration, and patient weight.Conclusions:In the UK, a cost per QALY below £20,000–30,000 is considered cost effective. Hence, the results from this economic analysis suggest deferasirox is cost effective in lower risk, transfusion-dependent, MDS patients. Limitations with the analysis include a lack of comparative randomised controlled trial evidence, in particular to differentiate survival and clinical outcomes for deferasirox and DFO.

Deferasirox

10.3111/13696998.2010.516203

Cite

Citations (12)